Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

de Groot JS, Ratze MA, van Amersfoort M, Eisemann T, Vlug EJ, Niklaas MT, Chin SF, Caldas C, van Diest PJ, Jonkers J, de Rooij J, Derksen PW.

J Pathol. 2018 Aug;245(4):456-467. doi: 10.1002/path.5099. Epub 2018 Jun 20.

PMID:
29774524
2.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

PMID:
29610289
3.

FOXO Transcription Factors Both Suppress and Support Breast Cancer Progression.

Hornsveld M, Smits LMM, Meerlo M, van Amersfoort M, Groot Koerkamp MJA, van Leenen D, Kloet DEA, Holstege FCP, Derksen PWB, Burgering BMT, Dansen TB.

Cancer Res. 2018 May 1;78(9):2356-2369. doi: 10.1158/0008-5472.CAN-17-2511. Epub 2018 Feb 12.

PMID:
29440168
4.

Variants in members of the cadherin-catenin complex, CDH1 and CTNND1, cause blepharocheilodontic syndrome.

Kievit A, Tessadori F, Douben H, Jordens I, Maurice M, Hoogeboom J, Hennekam R, Nampoothiri S, Kayserili H, Castori M, Whiteford M, Motter C, Melver C, Cunningham M, Hing A, Kokitsu-Nakata NM, Vendramini-Pittoli S, Richieri-Costa A, Baas AF, Breugem CC, Duran K, Massink M, Derksen PWB, van IJcken WFJ, van Unen L, Santos-Simarro F, Lapunzina P, Gil-da Silva Lopes VL, Lustosa-Mendes E, Krall M, Slavotinek A, Martinez-Glez V, Bakkers J, van Gassen KLI, de Klein A, van den Boogaard MH, van Haaften G.

Eur J Hum Genet. 2018 Feb;26(2):210-219. doi: 10.1038/s41431-017-0010-5. Epub 2018 Jan 18.

PMID:
29348693
5.

Shared mechanisms regulate spatiotemporal RhoA-dependent actomyosin contractility during adhesion and cell division.

Derksen PWB, van de Ven RAH.

Small GTPases. 2017 Dec 31:1-9. doi: 10.1080/21541248.2017.1366966. [Epub ahead of print]

PMID:
29291271
6.

Prophylaxis of hereditary breast cancer.

de Groot JS, van Diest PJ, Derksen PWB.

Aging (Albany NY). 2017 Dec 8;9(12):2453-2454. doi: 10.18632/aging.101342. No abstract available.

7.

Re-evaluating the role of FOXOs in cancer.

Hornsveld M, Dansen TB, Derksen PW, Burgering BMT.

Semin Cancer Biol. 2018 Jun;50:90-100. doi: 10.1016/j.semcancer.2017.11.017. Epub 2017 Nov 21. Review.

8.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

Raap M, Gronewold M, Christgen H, Glage S, Bentires-Alj M, Koren S, Derksen PW, Boelens M, Jonkers J, Lehmann U, Feuerhake F, Kuehnle E, Gluz O, Kates R, Nitz U, Harbeck N, Kreipe HH, Christgen M.

Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.

PMID:
29035379
9.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.

Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.

10.

Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer.

Bruner HC, Derksen PWB.

Cold Spring Harb Perspect Biol. 2018 Mar 1;10(3). pii: a029330. doi: 10.1101/cshperspect.a029330. Review.

PMID:
28507022
11.

p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.

van de Ven RA, de Groot JS, Park D, van Domselaar R, de Jong D, Szuhai K, van der Wall E, Rueda OM, Ali HR, Caldas C, van Diest PJ, Hetzer MW, Sahai E, Derksen PW.

Nat Commun. 2016 Dec 22;7:13874. doi: 10.1038/ncomms13874.

12.

Mesenchymal Cell Invasion Requires Cooperative Regulation of Persistent Microtubule Growth by SLAIN2 and CLASP1.

Bouchet BP, Noordstra I, van Amersfoort M, Katrukha EA, Ammon YC, Ter Hoeve ND, Hodgson L, Dogterom M, Derksen PWB, Akhmanova A.

Dev Cell. 2016 Dec 19;39(6):708-723. doi: 10.1016/j.devcel.2016.11.009. Epub 2016 Dec 8.

13.

p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice.

Tenhagen M, Klarenbeek S, Braumuller TM, Hofmann I, van der Groep P, Ter Hoeve N, van der Wall E, Jonkers J, Derksen PW.

J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):81-88. Epub 2016 Jul 13.

14.

Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer.

Hornsveld M, Tenhagen M, van de Ven RA, Smits AM, van Triest MH, van Amersfoort M, Kloet DE, Dansen TB, Burgering BM, Derksen PW.

Cell Death Differ. 2016 Sep 1;23(9):1483-92. doi: 10.1038/cdd.2016.33. Epub 2016 Apr 1.

15.

Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer.

van Brussel AS, Adams A, Oliveira S, Dorresteijn B, El Khattabi M, Vermeulen JF, van der Wall E, Mali WP, Derksen PW, van Diest PJ, van Bergen En Henegouwen PM.

Mol Imaging Biol. 2016 Aug;18(4):535-44. doi: 10.1007/s11307-015-0909-6.

16.

Methylation biomarkers for pleomorphic lobular breast cancer - a short report.

Moelans CB, Vlug EJ, Ercan C, Bult P, Buerger H, Cserni G, van Diest PJ, Derksen PW.

Cell Oncol (Dordr). 2015 Oct;38(5):397-405. doi: 10.1007/s13402-015-0241-9. Epub 2015 Sep 21.

17.

Nuclear p120-catenin regulates the anoikis resistance of mouse lobular breast cancer cells through Kaiso-dependent Wnt11 expression.

van de Ven RA, Tenhagen M, Meuleman W, van Riel JJ, Schackmann RC, Derksen PW.

Dis Model Mech. 2015 Apr;8(4):373-84. doi: 10.1242/dmm.018648. Epub 2015 Feb 20.

18.

Lobular breast cancer: pathology, biology, and options for clinical intervention.

Vlug E, Ercan C, van der Wall E, van Diest PJ, Derksen PW.

Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):7-21. Review.

PMID:
23959112
19.

p120-catenin in cancer - mechanisms, models and opportunities for intervention.

Schackmann RC, Tenhagen M, van de Ven RA, Derksen PW.

J Cell Sci. 2013 Aug 15;126(Pt 16):3515-25. doi: 10.1242/jcs.134411. Review.

20.

Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer.

Vlug EJ, van de Ven RA, Vermeulen JF, Bult P, van Diest PJ, Derksen PW.

Cell Oncol (Dordr). 2013 Oct;36(5):375-84. doi: 10.1007/s13402-013-0143-7. Epub 2013 Aug 15.

21.

FER kinase promotes breast cancer metastasis by regulating α6- and β1-integrin-dependent cell adhesion and anoikis resistance.

Ivanova IA, Vermeulen JF, Ercan C, Houthuijzen JM, Saig FA, Vlug EJ, van der Wall E, van Diest PJ, Vooijs M, Derksen PW.

Oncogene. 2013 Dec 12;32(50):5582-92. doi: 10.1038/onc.2013.277. Epub 2013 Jul 22.

22.

Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling.

Schackmann RC, Klarenbeek S, Vlug EJ, Stelloo S, van Amersfoort M, Tenhagen M, Braumuller TM, Vermeulen JF, van der Groep P, Peeters T, van der Wall E, van Diest PJ, Jonkers J, Derksen PW.

Cancer Res. 2013 Aug 1;73(15):4937-49. doi: 10.1158/0008-5472.CAN-13-0180. Epub 2013 Jun 3.

23.

Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study.

Vermeulen JF, van Brussel AS, Adams A, Mali WP, van der Wall E, van Diest PJ, Derksen PW.

Mol Imaging Biol. 2013 Jun;15(3):290-8. doi: 10.1007/s11307-012-0605-8.

24.

Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer.

Vermeulen JF, van de Ven RA, Ercan C, van der Groep P, van der Wall E, Bult P, Christgen M, Lehmann U, Daniel J, van Diest PJ, Derksen PW.

PLoS One. 2012;7(5):e37864. doi: 10.1371/journal.pone.0037864. Epub 2012 May 25.

25.

p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.

Ercan C, van Diest PJ, van der Ende B, Hinrichs J, Bult P, Buerger H, van der Wall E, Derksen PW.

Cell Oncol (Dordr). 2012 Apr;35(2):111-8. doi: 10.1007/s13402-012-0071-y. Epub 2012 Feb 22.

26.

Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells.

Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW, Voest EE.

Cancer Res. 2011 Nov 15;71(22):6976-85. doi: 10.1158/0008-5472.CAN-11-0627. Epub 2011 Oct 5.

27.

Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.

Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, Vermaat JS, Moerer P, Ishihara K, Kalkhoven E, Beijnen JH, Derksen PW, Medema RH, Martens AC, Brenkman AB, Voest EE.

Cancer Cell. 2011 Sep 13;20(3):370-83. doi: 10.1016/j.ccr.2011.08.010.

28.

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Schackmann RC, van Amersfoort M, Haarhuis JH, Vlug EJ, Halim VA, Roodhart JM, Vermaat JS, Voest EE, van der Groep P, van Diest PJ, Jonkers J, Derksen PW.

J Clin Invest. 2011 Aug;121(8):3176-88. doi: 10.1172/JCI41695. Epub 2011 Jul 11.

29.

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

Derksen PW, Braumuller TM, van der Burg E, Hornsveld M, Mesman E, Wesseling J, Krimpenfort P, Jonkers J.

Dis Model Mech. 2011 May;4(3):347-58. doi: 10.1242/dmm.006395. Epub 2011 Jan 31.

30.

Intravital microscopy: new insights into metastasis of tumors.

Beerling E, Ritsma L, Vrisekoop N, Derksen PW, van Rheenen J.

J Cell Sci. 2011 Feb 1;124(Pt 3):299-310. doi: 10.1242/jcs.072728. Review.

31.

Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells.

Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, Raats DA, Sprick MR, Schaefer U, Van Houdt WJ, De Bruijn MT, Schackmann RC, Derksen PW, Medema JP, Walczak H, Borel Rinkes IH, Kranenburg O.

Gastroenterology. 2010 Jun;138(7):2357-67. doi: 10.1053/j.gastro.2010.02.046. Epub 2010 Feb 23.

PMID:
20188103
32.

A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis.

Evers B, Speksnijder EN, Schut E, Ciampricotti M, Smalley MJ, Derksen PW, Jonkers J, de Visser KE.

J Pathol. 2010 Jan;220(1):34-44. doi: 10.1002/path.2655.

PMID:
19927317
33.

Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival.

Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, Gray NS, Jonkers J, Rosen JM, Brugge JS.

Cancer Res. 2009 Mar 15;69(6):2244-51. doi: 10.1158/0008-5472.CAN-08-3398. Epub 2009 Mar 3. Erratum in: Cancer Res. 2009 Aug 1;69(15):6366.

34.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

35.

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.

Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren A, Went P, Derksen PW, Berns A, Jonkers J, Christofori G.

EMBO J. 2008 Oct 8;27(19):2603-15. doi: 10.1038/emboj.2008.178. Epub 2008 Sep 4.

36.

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J.

Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953.

37.

Modeling metastatic breast cancer in mice.

Jonkers J, Derksen PW.

J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):191-203. Review.

PMID:
17587153
38.

Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J.

Cancer Cell. 2006 Nov;10(5):437-49.

39.

Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.

Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M.

Blood. 2006 Jan 15;107(2):760-8. Epub 2005 Sep 27.

40.

Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator.

Tjin EP, Bende RJ, Derksen PW, van Huijstee AP, Kataoka H, Spaargaren M, Pals ST.

J Immunol. 2005 Sep 1;175(5):2807-13.

41.

MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling.

Boon EM, Kovarikova M, Derksen PW, van der Neut R.

Br J Cancer. 2005 Mar 28;92(6):1078-83.

42.

Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator.

Tjin EP, Derksen PW, Kataoka H, Spaargaren M, Pals ST.

Blood. 2004 Oct 1;104(7):2172-5. Epub 2004 Jun 1.

43.

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST.

Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7. Epub 2004 Apr 5.

44.

Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.

Heideman DA, van Beusechem VW, Bloemena E, Snijders PJ, Craanen ME, Offerhaus GJ, Derksen PW, de Bruin M, Witlox MA, Molenaar B, Meijer CJ, Gerritsen WR.

J Gene Med. 2004 Mar;6(3):317-27.

PMID:
15026993
45.

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST.

Leukemia. 2003 Apr;17(4):764-74.

PMID:
12682635
46.

Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration.

Taher TE, Derksen PW, de Boer OJ, Spaargaren M, Teeling P, van der Wal AC, Pals ST.

Biochem Biophys Res Commun. 2002 Oct 18;298(1):80-6.

PMID:
12379223
47.

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.

Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST.

Blood. 2002 Feb 15;99(4):1405-10.

48.

Limitations of clonality analysis of B cell proliferations using CDR3 polymerase chain reaction.

Hoeve MA, Krol AD, Philippo K, Derksen PW, Veenendaal RA, Schuuring E, Kluin PM, van Krieken JH.

Mol Pathol. 2000 Aug;53(4):194-200.

49.

The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation.

van der Voort R, Taher TE, Derksen PW, Spaargaren M, van der Neut R, Pals ST.

Adv Cancer Res. 2000;79:39-90. Review.

PMID:
10818677
50.

Comparison of different polymerase chain reaction-based approaches for clonality assessment of immunoglobulin heavy-chain gene rearrangements in B-cell neoplasia.

Derksen PW, Langerak AW, Kerkhof E, Wolvers-Tettero IL, Boor PP, Mulder AH, Vrints LW, Coebergh JW, van Krieken JH, Schuuring E, Kluin PM, van Dongen JJ.

Mod Pathol. 1999 Aug;12(8):794-805.

PMID:
10463482

Supplemental Content

Loading ...
Support Center